about
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosusA regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humansA STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosusCoronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variantsThe R620W C/T polymorphism of the gene PTPN22 is associated with SLE independently of the association of PDCD1.Identification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE)Genetic risk factors in lupus nephritis and IgA nephropathy--no support of an overlap.Case definitions in Swedish register data to identify systemic lupus erythematosus.Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays.Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis.Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeRisk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study.IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE).Copy number, linkage disequilibrium and disease association in the FCGR locus.Role of early repeated renal biopsies in lupus nephritis.No evidence of association between genetic variants of the PDCD1 ligands and SLE.A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE.A research study of the association between maternal microchimerism and systemic lupus erythematosus in adults: a comparison between patients and healthy controls based on single-nucleotide polymorphism using quantitative real-time PCREvaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis.Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren's syndrome and systemic lupus erythematosusIncreased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus.Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus.No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab.Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-upThree functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus.Antiphospholipid Antibodies in Lupus Nephritis.A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5.Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populationsOfatumumab treatment in lupus nephritis patients.Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations.What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLEInterferon (IFN)-λ is a potential mediator in lupus nephritisIschemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based case-control study.Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus.Prevention of cardiovascular disease in rheumatoid arthritis.Novel risk genes for systemic lupus erythematosus predicted by random forest classification
P50
Q24629130-03A61027-98C8-4BE5-B3EE-07FBF07802C5Q28211167-15BC57C4-1602-4AFC-A8C6-D43324F94562Q28258975-A5E6A63A-82CB-4E8A-BCDD-5B8A01AB81CCQ28290376-BCBCA119-E98B-4FA7-A14E-1BB01D36ED4DQ30160168-83158193-A290-42ED-9387-D7E317EB5315Q30973856-1192D9CB-721B-42C4-88E8-DE0336FD288FQ30982765-A8ADD25D-26B4-4B4E-8CCE-F1FB353EBCA3Q31034949-3C982E54-83F0-4CDE-A300-A347F322145AQ33387473-F152CF27-1B97-4C67-AAD9-F91B88A80527Q33404418-D57CAEFC-C206-407F-BA69-536CE99577E3Q33428711-0749BEB9-B2CA-43F2-B406-39603CD7CD28Q33570432-13F29ADE-9B58-4BCE-AE52-B915FFF2C1AFQ33570432-99787D72-B2C3-4202-8FD5-9B6EB75AE622Q33731711-9C2F4B5D-2B3B-4E19-932D-B36A269AC897Q33766242-506954A2-ACFB-4A47-B0BD-41DD627C7AA2Q33801351-0995E0D7-BE16-47C8-996F-26E8E14EFDADQ34013523-2FE99213-7B6E-42C8-BEF2-0855298CD786Q34424633-73391B76-B87B-4C2F-8291-497443D2E427Q34585940-030E88E5-5A46-41A5-9057-2D3007382B85Q34694711-AA36845E-4232-4970-867E-F95DB2745998Q34990102-2C3BBDEB-769C-461B-BC58-C0C4F2D9DCC5Q35008162-4F7F1782-0EC2-48CE-AC96-1799E30173BFQ35080952-BCCFC03E-9F4F-49B6-8155-11B083E9BCE3Q35548228-1ED389EE-3AF9-4D55-9AAA-8BD359835A5EQ35550296-4BB2191F-4A01-4290-BD67-3406FE8F59B4Q35585133-3055CF79-D8B6-45C7-8446-BBA57DEF03B7Q35637868-6D5F678A-A4DF-49EA-AA3A-41B3E21D1B19Q35645573-9739EC99-55D2-4045-AD22-7C4E59B08F77Q35741943-B96F5CB3-2082-40EB-AA17-72AA5D29CE70Q35907818-EA1920E8-289A-4816-8E33-B9BF6FAD7DE0Q36060060-9E4B1660-4997-4CBA-B302-3B7E48FB1709Q36851638-9E82380E-FD27-44C3-9A53-6A24FB8AFEE1Q37102098-0079DB39-F102-41EA-A500-0FAB3040523AQ37119045-66425876-6F60-4972-9873-B3454EBB24D3Q37363894-CD1E58E9-0B90-4EB5-BD39-5B72C7E40C55Q37392157-B24DB140-93FF-49D0-8131-DDD64B80F73CQ37464013-E5912814-75C4-463F-997D-156A6546320FQ37690928-9AEACA64-A7B6-42DE-8863-BF3300BD9E1DQ38162490-557ED9CC-9E56-491E-A32C-DD8A8AC06F7CQ38539171-3271BF12-6954-4D22-82AC-FB5443BA3EEA
P50
description
Zweeds onderzoekster
@nl
hulumtuese
@sq
professor, adjungerad Karolinska institutet
@sv
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Elisabet Svenungsson
@ast
Elisabet Svenungsson
@en
Elisabet Svenungsson
@es
Elisabet Svenungsson
@ga
Elisabet Svenungsson
@nl
Elisabet Svenungsson
@sl
Elisabet Svenungsson
@sq
Elisabet Svenungsson
@sv
type
label
Elisabet Svenungsson
@ast
Elisabet Svenungsson
@en
Elisabet Svenungsson
@es
Elisabet Svenungsson
@ga
Elisabet Svenungsson
@nl
Elisabet Svenungsson
@sl
Elisabet Svenungsson
@sq
Elisabet Svenungsson
@sv
prefLabel
Elisabet Svenungsson
@ast
Elisabet Svenungsson
@en
Elisabet Svenungsson
@es
Elisabet Svenungsson
@ga
Elisabet Svenungsson
@nl
Elisabet Svenungsson
@sl
Elisabet Svenungsson
@sq
Elisabet Svenungsson
@sv
P106
P2038
Elisabet_Svenungsson
P21
P27
P31
P496
0000-0003-3396-3244
P569
1955-02-03T00:00:00Z